CAMBRIDGE, Mass., May 15, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) today announced that new preclinical data from its Duchenne muscular dystrophy (DMD) programs, including its lead gene transfer candidate, SGT-001, will be presented at the 21^st Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT) held May 16-19, 2018 in Chicago.

Oral Presentations:

• AAV Micro-Dystrophin Therapy Ameliorates Muscular Dystrophy in Young Adult Duchenne Muscular Dystrophy Dogs for Up to Thirty Months Following Injection
  Abstract Number: 8
  Date/Time: Wednesday, May 16^th at 10:45 a.m. CT

• Identification of Novel AAV Capsids for Skeletal Muscle Gene Transfer By In Vivo Selection in Humanized Mice
  Abstract Number: 355
  Date/Time: Thursday, May 17^th at 4:30 p.m. CT

Poster Presentations:

• Assessing Anti-Dystrophin T-Cell Responses by Elispot Following AAV9-Microdystrophin Gene Therapy in Dogs
  Abstract Number: 219
  Date/Time: Wednesday, May 16^th at 5:30 p.m. CT

• In Vivo Comparison of the Biological Potency of rAAV9-Microdystrophin Made by Transient Transfection and a Scalable Herpesvirus System 
  Abstract Number: 626
  Date/Time: Thursday, May 17^th at 5:15 p.m. CT

• In Silico Platform for the Design and Generation of Novel Muscle Promoters: In Vitro Validation 
  Abstract Number: 869
  Date/Time: Friday, May 18^th at 5:45 p.m. CT

• Preclinical Evaluation of SGT-001 Microdystrophin Gene Transfer for Duchenne Muscular Dystrophy
  Abstract Number: 854
  Date/Time: Friday, May 18^th at 5:45 p.m. CT

• Complementary Techniques to Evaluate Microdystrophin Expression in Duchenne Muscular Dystrophy Gene Therapy Studies
  Abstract Number: 868
  Date/Time: Friday, May 18^th at 5:45 p.m. CT

About Solid Biosciences
Solid Biosciences is a life science company focused solely on finding meaningful therapies for Duchenne muscular dystrophy (DMD). Founded by those touched by the disease, Solid is a center of excellence for DMD, bringing together experts in science, technology and care to drive forward a portfolio of candidates that have life-changing potential. Solid is progressing programs across four scientific platforms: Corrective Therapies, Disease-Modifying Therapies, Disease Understanding and Assistive Devices. Solid’s lead clinical candidate for DMD is a novel adeno-associated viral (AAV) vector-mediated microdystrophin gene transfer called SGT-001. The Phase I/II clinical trial for SGT-001, IGNITE DMD, is currently on clinical hold.  For more information, please visit www.solidbio.com.

Contact:
Solid Biosciences
Kate Niazi-Sai
+1 617-337-4680
media@solidbio.com 
investors@solidbio.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.